Clinical trials: CART Cells
Lymphoma, B-Cell
Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with relapsed/refractory B Cell Lymphoma.
- Trial name
- NCT04163302
- Testing
- CD19-PD1-CART Cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma.
- Trial name
- NCT06066346
- Testing
- Talquetamab
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed and Refractory Multiple Myeloma (RRMM)
SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
This is a Phase I, single-center, single-arm, open-label clinical study to evaluate the safety, tolerability, and preliminary efficacy of SL4903 autologous T-cell injection (CAR-T cell therapy) in adult patients with relapsed or…
- Trial name
- SL4903 (NCT07234721)
- Testing
- SL4903 Autologous T-Cell Injection
- Volunteers
- 9 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal…
- Trial name
- NCT07489534
- Testing
- PD-1Ab21-BCMA CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Daihong Liu
Adult B Acute Lymphoblastic Leukemia
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed Refractory (R/R) adult acute lymphoblastic…
- Trial name
- NCT04626726
- Testing
- CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Advanced Hepatocellular Carcinoma
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
A Phase I Clinical Trial for Evaluating the Safety, Tolerance and Efficacy of GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
- Trial name
- NCT05352542
- Testing
- GPC3 Targeting CART Cells
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- jianming xu
Diffuse Large B Cell Lymphoma, CAR-T
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
This is a single-arm single center study to prospectively evaluate the safety and efficacy of ultra-fraction radiotherapy bridging CAR-T therapy in relapsed/refractory diffuse large b cell lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy, Bridging Therapy
- Trial name
- NCT05514327
- Testing
- ultra-fraction radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
B Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies
CD19 is expressed in most B malignant tumors, especially in the former B cells ALL. This makes CD19 a natural target of immunotherapy.
- Conditions
- B Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04184414
- Testing
- CD19-CART
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Non-Hodgkin Lymphoma Refractory/ Relapsed
Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL
This is a Prospective Single Center, open label, Non-randomized, Single Arm, Single Dose, Phase II Clinical Trial. Adult patients >18-year-old with CD19+ Non-Hodgkin lymphoma are eligible for the study if they meet eligibility…
- Trial name
- NCT07271121
- Testing
- MB-CART-19.1
- Where
- Jordan
- Volunteers
- 26 people
- Sponsor
- King Hussein Cancer Center
Multiple Myeloma, Refractory to Standard Treatment, Multiple Myeloma, Relapsed
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.
- Conditions
- Multiple Myeloma, Refractory to Standard Treatment, Multiple Myeloma, Relapsed, Light Chain Amyloidosis
- Trial name
- NCT06971380
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 180 people
- Sponsor
- Polina Stepensky
Multiple Myeloma in Remission
Universal CAR-T Cells Targeting Multiple Myeloma
The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T…
- Trial name
- NCT06006741
- Testing
- MM-specific universal CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.
- Trial name
- NCT07874334
- Testing
- GPRC5D CART
- Where
- Israel
- Volunteers
- 160 people
- Sponsor
- Hadassah Medical Organization
Multiple Myeloma (MM)
CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)
Multiple myeloma patients can be treated with cell therapy, which uses some of their own modified white blood cells (T lymphocytes) to target a protein (BCMA, or B-cell maturation antigen) found on the surface of the myeloma…
- Trial name
- CART I5M (NCT07342179)
- Testing
- Additional Bone Marrow cells and blood sampling
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Poitiers University Hospital
Relapsed/Refractory Multiple Myeloma
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.
- Trial name
- NCT04309981
- Testing
- Adult differentiated autologous T-cells with anti-BCMA specificity
- Where
- 7 sites in Spain
- Volunteers
- 73 people
- Sponsor
- Sara V. Latorre
Non-Small Cell Lung Cancer, Ovarian Cancer
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express…
- Conditions
- Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04025216
- Testing
- CART-TnMUC1, Cyclophosphamide, Fludarabine
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kite, A Gilead Company
Ovarian Cancer
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer
- Trial name
- NCT03814447
- Testing
- anti- MESO CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai 6th People's Hospital
T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type
CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
Phase I was a single arm, open label, dose increasing study to explore the safety, tolerance and Cytodynamic characteristics of the drug, and to preliminarily observe the efficacy of the study drug in relapsed / refractory CD7…
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT04480788
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 9 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Rheumatoid Arthritis
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans.
- Trial name
- Regulate-RA (NCT06201416)
- Testing
- SBT777101
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sonoma Biotherapeutics, Inc.
Multiple Myeloma
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients
- Trial name
- NCT04287660
- Testing
- clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion
Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies
This is a non-therapeutic, long-term follow-up (LTFU) study of subjects who have received retroviral-based gene therapy products in cancer studies.
- Trial name
- NCT02666248
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania